CA.ME.LI.A. An epidemiological study on the prevalence of CArdiovascular, MEtabolic, LIver and Autoimmune diseases in Northern Italy.

[1]  R. DeFronzo,et al.  Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. , 2020, Metabolism: clinical and experimental.

[2]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[3]  D. Baldassarre,et al.  Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population. , 2019, International journal of cardiology.

[4]  M. Iriti,et al.  Bioactive phytochemicals of tree nuts. Determination of the melatonin and sphingolipid content in almonds and pistachios , 2019, Journal of Food Composition and Analysis.

[5]  F. Folli,et al.  Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). , 2018, Pharmacological research.

[6]  O. Barbarash,et al.  Localization of fat depots and cardiovascular risk , 2018, Lipids in Health and Disease.

[7]  A. Konradi,et al.  Epidemiology of cardiovascular risk factors in two population-based studies. , 2018, Atherosclerosis. Supplements.

[8]  P. Francesconi,et al.  FP354PREVALENCE OF CHRONIC KIDNEY DISEASE IN ITALY: THE ROLE OF DEMOGRAPHIC SHIFT TOWARDS OLDER AGE GROUPS , 2018 .

[9]  A. Lonardo,et al.  Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? , 2018, Journal of hepatology.

[10]  F. Valente,et al.  Hypertriglyceridemia, an Underestimated Cardiovascular Risk Factor: An Epidemiological Study of the Rome Area , 2017, High Blood Pressure & Cardiovascular Prevention.

[11]  G. Marchesini,et al.  AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  C. Caserta,et al.  Seroepidemiology of HEV and HAV in two populations with different socio-economic levels and hygienic/sanitary conditions , 2017, European Journal of Clinical Microbiology & Infectious Diseases.

[13]  Meric Erikci Ertunc,et al.  Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment , 2016, Journal of Lipid Research.

[14]  Amjad M Ahmed,et al.  Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study , 2016, Journal of the Saudi Heart Association.

[15]  E. Benjamin,et al.  The Future of Cardiovascular Epidemiology , 2016, Circulation.

[16]  Luigi Palmieri,et al.  Cardiovascular health in Italy. Ten-year surveillance of cardiovascular diseases and risk factors: Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey 1998–2012 , 2015, European journal of preventive cardiology.

[17]  G. Sesti,et al.  Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease , 2014, BMJ Open Diabetes Research and Care.

[18]  H. Sillesen.  Carotid intima-media thickness and/or carotid plaque: what is relevant? , 2014, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[19]  R. DeFronzo,et al.  Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study , 2013, Diabetologia.

[20]  M. Federici,et al.  The role of ADAM17 in metabolic inflammation. , 2013, Atherosclerosis.

[21]  Enzo Grossi,et al.  Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) study. , 2012, Journal of the American College of Cardiology.

[22]  L. Piemonti,et al.  Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up , 2012, Acta Diabetologica.

[23]  S. Menini,et al.  Overexpression of Tissue Inhibitor of Metalloproteinase 3 in Macrophages Reduces Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[24]  A. Rubinstein,et al.  Cardiovascular disease research in Latin America: a comparative bibliometric analysis. , 2011, World journal of cardiology.

[25]  Paolo Crosignani,et al.  Fatty liver index and mortality: The cremona study in the 15th year of follow‐up , 2011, Hepatology.

[26]  E. Trabetti,et al.  Variants of GCKR Affect Both β-Cell and Kidney Function in Patients With Newly Diagnosed Type 2 Diabetes , 2011, Diabetes Care.

[27]  M. Reilly,et al.  Gender differences in the association of C‐reactive protein with coronary artery calcium in Type‐2 diabetes , 2011, Clinical endocrinology.

[28]  L. Luzi,et al.  Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals , 2010, Diabetes Care.

[29]  Eric Boerwinkle,et al.  Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. , 2010, Journal of the American College of Cardiology.

[30]  A. Gasbarrini,et al.  Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[31]  R. DeFronzo,et al.  Impaired regulation of the TNF-α converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans , 2009, Diabetologia.

[32]  Makoto Watanabe,et al.  Cardiovascular Disease and Risk Factors in Asia: A Selected Review , 2008, Circulation.

[33]  Poonam Mishra,et al.  Abdominal Ultrasound for Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) , 2007, The American Journal of Gastroenterology.

[34]  M. Criqui,et al.  Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. , 2006, American heart journal.

[35]  D. Accili,et al.  Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. , 2005, The Journal of clinical investigation.

[36]  A. Naska,et al.  Mediterranean diet in relation to body mass index and waist-to-hip ratio: the Greek European Prospective Investigation into Cancer and Nutrition Study. , 2005, The American journal of clinical nutrition.

[37]  A. Khera,et al.  Race and gender differences in C-reactive protein levels. , 2005, Journal of the American College of Cardiology.

[38]  S. Haffner,et al.  Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. , 2005, Diabetes care.

[39]  J. Tuomilehto,et al.  Trends in obesity and energy supply in the WHO MONICA Project , 2004, International Journal of Obesity.

[40]  G. Berenson.  Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. , 2002, The American journal of cardiology.

[41]  G. Reaven,et al.  Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. , 1999, Metabolism: clinical and experimental.

[42]  A. Nissinen,et al.  Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up , 1996 .

[43]  G. Gallus,et al.  Epidemiology of known diabetes in Lombardy, north Italy , 1995, Acta Diabetologica.

[44]  D Kromhout,et al.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. , 1995, JAMA.

[45]  E. Bonora,et al.  The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality , 1995, Diabetologia.

[46]  E. Bonora,et al.  Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. , 1989, The New England journal of medicine.

[47]  V. Lorenzoni,et al.  The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: a multicenter study in Italy. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[48]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[49]  L. Freedman.  Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.